Morgan Stanley’s Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 CMRAW Stock Holding History

Morgan Stanley’s Portfolio CMRAW Stock Details CMRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,146	Closed	-$25	–	7995
2023 Q3	$25	Hold	1,146	–	–	﹤0.01%	7528
2023 Q2	$31	Hold	1,146	–	–	﹤0.01%	7566
2023 Q1	$49	Hold	1,146	–	–	﹤0.01%	7610
2022 Q4	$55	Hold	1,146	–	–	﹤0.01%	7729
2022 Q3	$0	Hold	1,146	–	–	﹤0.01%	7991
2022 Q2	$0	Buy	+1,146	New	+$188	﹤0.01%	8095

Other funds holding CMRAW

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Morgan Stanley's CMRAW Position: Q4 2023 in Review

Morgan Stanley sold out of Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 (CMRAW) in Q4 2023, closing a stake of 1,146 shares — an estimated $25 sold.

Morgan Stanley first reported a position in CMRAW in Q2 2022 and held it in 6 quarters. The position peaked at $55 in Q4 2022. 3 funds tracked by Wall St. Rank hold CMRAW as of Q4 2023.

Morgan Stanley reported no remaining Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 position as of Q4 2023 after selling out during the quarter.
Morgan Stanley sold 1,146 Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 shares in Q4 2023, an estimated $25.
Morgan Stanley first reported a position in Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 in Q2 2022 and held it in 6 quarters.
Morgan Stanley's Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 position peaked at $55 in Q4 2022.
3 funds tracked by Wall St. Rank held Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 as of Q4 2023.

Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.